Rabu, 18 Januari 2012

$3.58 Million Gift Will Forward Scientific Advances For Mesothelioma Research, One Of The Most Difficult To Treat Cancers


The UH Cancer Center has received a $3.58 million gift from an anonymous donor to support the mesothelioma research of Dr. Michele Carbone, director of the UH Cancer Center. Carbone and colleagues, who include Drs. Haining Yang and Giovanni Gaudino, have made a series of recent scientific breakthroughs that will lead to new ways to prevent and treat the disease.

"This generous gift is critical to support our efforts to generate discoveries that will aid in the prevention of mesothelioma and the development of new therapies," said Dr. Carbone. Mesothelioma is a cancer of the cells that line the chest and abdominal cavities. It results in one of the most aggressive types of tumors, and current median survival from diagnosis is just twelve months. Exposure to airborne asbestos or erionite particles increases one's risk of developing mesothelioma.


The gift is the second largest in UH Cancer Center history. "Mesothelioma is a serious public health problem," said Dr. Virginia Hinshaw, Chancellor of UH Manoa. "We're proud that Dr. Carbone's team is leading the world in this area of discovery. This gift validates their efforts and will help them remain at the forefront of thoracic oncology research."


Dr. Carbone and colleagues have studied mesothelioma for more than a decade. Significant findings have come from studies conducted in the villages of Capadoccia, a region of Turkey. Dubbed "death villages," nearly 50% of the area's residents develop and die of mesothelioma. The epidemic is caused by exposure to a fiber called erionite that is even more potent than asbestos in causing mesothelioma. Erionite is a naturally occurring mineral found in rock formations and homes built of rock material in the region. The team's findings led to a response from the Turkish government that included building the villagers new homes and a regional health center to conduct treatment.


Dr. Carbone and collaborators will conduct a clinical trial co-sponsored by the Early Detection Research Network of the U.S. National Cancer Institute and the Turkish Ministry of Health to validate serum biomarkers they discovered for the early detection of mesothelioma.


This past winter, Dr. Carbone reported new findings describing potential erionite exposure in the U.S. (Nature, Dec. 16, 2010). Collaborating with scientists at the Environmental Protection Agency and the National Institutes of Health, they found evidence of erionite in rock materials used to pave roads in North Dakota and other states. Public health concerns have been raised and the team's examination continues in partnership with the EPA. Findings from a new detailed study were presented at a recent scientific meeting and are pending publication in a leading scientific journal. The National Institutes of Health has planned a conference this fall to discuss potential public health issues related to erionite exposure."


Source:
Kellie Tormey
University of Hawaii Cancer Center

Article adapted by Medical News Today from original press release.
Visit our asbestos / mesothelioma section for the latest news on this subject. There are no references listed for this article. Please use one of the following formats to cite this article in your essay, paper or report:

View the original article here

1st International Symposium On Lung-Sparing Therapies For Malignant Pleural Mesothelioma

The UCLA Mesothelioma Research Program is sponsoring the 1st International Symposium on Lung-Sparing Therapies for Malignant Pleural Mesothelioma (MPM) at the Sheraton Hotel in Santa Monica, California. This unique one-day symposium will take place on Saturday, May 21st from 8:00 a.m. to 5:00 p.m.

The course will be led by Dr. Robert Cameron, MD, FACS, Director of the Mesothelioma Research Program at the David Geffen School of Medicine at UCLA, Chief of Thoracic Surgery at the West Los Angeles Veterans' Administration Medical Center, and a long-time advocate for lung-sparing surgery.


The seminar's distinguished international faculty includes both Mr. Tom Treasure, MD and Mr. David A Waller, MD, who will discuss the recent results announced from the Mesothelioma and Radical Surgery (MARS) Trial conducted in the U.K. The program will feature additional experts in the fields of surgery, radiation, chemotherapy and pulmonary medicine. The symposium was designed primarily for physicians needing continuing medical education (CME) credit but other interested parties may attend.


For a brochure on the seminar and to enroll online, go here.


Source:
UCLA Mesothelioma Research Program

Article adapted by Medical News Today from original press release.
Visit our conferences section for the latest news on this subject. There are no references listed for this article. Please use one of the following formats to cite this article in your essay, paper or report:

MLA

UCLA Mesothelioma Research Program. "1st International Symposium On Lung-Sparing Therapies For Malignant Pleural Mesothelioma." Medical News Today. MediLexicon, Intl., 9 May. 2011. Web.
16 Jan. 2012. APA

Note: Any medical information published on this website is not intended as a substitute for informed medical advice and you should not take any action before consulting with a health care professional. For more information, please read our terms and conditions.



View the original article here

Selasa, 17 Januari 2012

Novel Anti-Mesothelioma Strategy

A drug commonly used to treat kidney cancer may increase the effectiveness of chemotherapy for mesothelioma, according to a study published in the May issue of the Journal of Thoracic Oncology.

Temsirolimus, a kinase inhibitor, blocks the action of mammalian target of rapamycin (mTOR), a protein that regulates cell growth, which can slow tumor growth. It's used to treat advanced renal cell carcinoma.


But researchers in Austria have found that temsirolimus also may slow the growth of malignant pleural mesothelioma cells. Mesothelioma, a cancer that is usually caused by exposure to asbestos and may not appear until 30 to 50 years after exposure, frequently resists chemotherapy and radiation treatment.


The researchers found that temsirolimus strongly blocked mTOR-mediated signals and had a cytostatic, or growth-stopping, effect on all mesothelioma cells. However, mesothelioma cells that were resistant to cisplatin, a widely used chemotherapy drug, showed hypersensitivity against temsirolimus.


That suggests that mTOR inhibitors like temsirolimus might be a promising treatment strategy either in combination with chemotherapy or as second-line treatment after chemotherapy failure.


"Malignant mesothelioma is a severe human malignancy characterized by a very bad prognosis, with a mean patient survival time of less than one year," said Professor Walter Berger, PhD, of the Institute of Cancer Research at the Medical University of Vienna. "This unacceptable situation is mainly caused by late diagnosis combined with a distinct resistance to all forms of systemic therapy available so far. Mesothelioma is frequently caused by asbestos exposure and unfortunately - based on the long latency period - the incidence peak lies, despite the ban on asbestos, still ahead. Consequently, novel therapeutic options for this devastative disease are urgently needed.


"In our preclinical study, published in the JTO, we were able to demonstrate that inhibition of the major oncogene mTOR is active against human mesothelioma especially after development of chemotherapy resistance both in vitro and in vivo," Berger said. "These results suggest the initiation of clinical trials involving mTOR inhibitors as a novel anti-mesothelioma strategy."


The study was supported by the Medical Scientific Fund of the Mayor of the City of Vienna, Initiative Krebsforschung of the Medical University Vienna, and a Wyeth/Pfizer research grant.


Source:
Renée McGaw
International Association for the Study of Lung Cancer

Article adapted by Medical News Today from original press release.
Visit our asbestos / mesothelioma section for the latest news on this subject. There are no references listed for this article. Please use one of the following formats to cite this article in your essay, paper or report:

MLA

Renée McGaw. "Novel Anti-Mesothelioma Strategy." Medical News Today. MediLexicon, Intl., 1 May. 2011. Web.
16 Jan. 2012. APA

 



View the original article here

Senin, 16 Januari 2012

What Is Mesothelioma? Cancer From Asbestos

Mesothelioma, more precisely known as malignant mesothelioma is a rare cancer of the mesothelial cells, most commonly those in the lining that covers the lungs (pleura). Mesothelial cells exist in the lining (membrane) that covers the outer surface of our body organs. The majority of people with mesothelioma have been exposed to asbestos at some time during their life.

Doctors usually divide mesothelioma into three types: Pleural mesothelioma - affects the pleura, the lining surrounding the lungs. This is the most common form.Peritoneal mesothelioma - the cancer attacks the lining of the abdomen, the peritoneum. This is the second most common form.Pericardial mesothelioma - the cancer attacks the protective layer covering the heart. This is the rarest form.All three forms of mesothelioma are nearly always caused by asbestos exposure.

Mesothelioma is an aggressive form of cancer. For the majority of patients there is no cure. Doctors usually focus on improving the quality of life as the disease progresses - making the patient as comfortable as possible.


In the United Kingdom, approximately 2,000 patients are diagnosed with mesothelioma annually. According to the CDC (Centers for Disease Control and Prevention), mesothelioma kills over 2,700 people in the USA every year. According to the Mesothelioma register, deaths from this type of cancer rose more than tenfold from 1969 to 2009 in the UK. About four-fifths of all deaths are among men.


According to Medilexicon's medical dictionary, mesothelioma is:


"A rare neoplasm derived from the lining cells of the pleura or peritoneum that grows as a thick sheet covering the viscera and is composed of spindle cells or fibrous tissue that may enclose glandlike spaces lined by cuboidal cells."
A symptom is something the patient feels and describes; while a sign is something other people can see, including doctors and nurses. For example, a symptom may be pain, while a sign could be a rash.

Exposure to asbestos and asbestos dust can take up to thirty years to show symptoms. Often, patients are diagnosed when the disease is already advanced. Outcomes depend on how early the malignancy can be diagnosed.


Mesothelioma signs and symptoms vary, depending on where in the body the cancer is.


Pleural mesothelioma (tissue surrounding the lungs) Shortness of breathCoughing, often painfulUnexpected and unexplained loss of weightPain under the rib cageSometimes lumps may be detectable under the skin in the chest areaLower back painDiscomfort in the side of the chestExhaustionSome people may experience sweating, fever, or difficulty swallowingPeritoneal mesothelioma (lining in the abdomen) Unexplained weight lossPain in the abdomenSwelling in the abdomenLumps in the abdomenNausea, some patients may experience vomitingPericardial mesothelioma (lining in the heart area) Low blood pressureShortness of breathFluid retention (edema), often in the legsHeart palpitationsFatigue, extreme after light exertionChest painExperts say that prolonged exposure to asbestos particles is the primary cause of mesothelioma. The risk of developing the disease is closely linked to asbestos particle dosage - i.e. the likelihood of developing mesothelioma is directly proportional to how long a person was exposed, and how much they inhaled.

People in jobs where exposure to asbestos fibers are common have the highest risk of developing the disease. Asbestos was commonly used for insulation, soundproofing, fireproofing, roofing, and ironing board covers.

Industries that may have involved asbestos exposure for some of their workpeople include constructions sites, steel mills, shipyards, oil refineries and power plants.

When the asbestos particles or fibers are inhaled or ingested, they build up in the lining of the abdomen, chest or lungs. This accumulation considerably increases the chances of cancerous cells developing.


When asbestos is damaged and particles or fibers are released into the air, the environment can become hazardous to human health. The fibers can be breathed in or swallowed, they get embedded in tissue, and eventually lead to mesothelioma.


Asbestos is a group of minerals that occur naturally. They exist as fibers or bundles. These fibers may be found in soil or rocks and exist in many parts of the world naturally. Asbestos is made of silicon, oxygen and some other elements.


There are two principle types of asbestos fibers: Serpentine asbestos - this is the most common type used in industry. It is known as white asbestos, or chrysotile. The fibers are curly.Amphibole asbestos - these include anthophyllite, amosite, actinolite, crocidolite, and tremolite. The fibers are straight, like needles. This type of asbestos, particularly crocidolite, is considered to be more likely to cause cancer. However, even serpentine asbestos has been linked to cancer.Although asbestos is much less used today than it used to be, exposure is still possible, and continues to be a serious problem. Older materials containing asbestos can break down, releasing a dust composed of tiny particles than can be inhaled or ingested. Exposure can occur when older buildings are demolished or renovated.

Even family members who never set foot in a working environment that contained asbestos can be exposed. The fibers can be carried home in the workers clothing, and then breathed in by other members of the household.


Asbestos can also be swallowed, as may occur when water flows through asbestos cement pipes. Inhaled asbestos can be coughed up, and then swallowed (when the person swallows the saliva).


WHO (World Health Organization) in 2005 said that approximately 125 million people globally were exposed to asbestos at work in that year, despite their employers having known about the link to cancer and other lung diseases for over six decades. Most work-related exposure today occurs in developing nations.


In much rarer cases, mesothelioma may be linked to irradiation, the inhalation of eronite or some other fibrous silicate, and intrapleural thorium dioxide (Thorotrast - a suspension containing radioactive particles, used in X-ray diagnostics during the 1930s and 1940s, and even in the 1950s in some nations including the USA). Some experts believe that SV40 (simian virus 40) could be involved in the development of the disease. A digital chest x-ray of advanced malignant mesothelioma
Digital chest x-ray of advanced malignant mesothelioma (on left) After asking certain diagnostic questions, such as the patient's symptoms, where he/she has worked, medical history and family history, and carrying out a physical examination, the doctor may order some imaging scans. This could be a CT scan or X-ray of the abdomen or chest to rule out any abnormalities. Usually, depending on the results of the scans, further testing may be recommended.

Biopsy - some tissue is surgically removed so that it can be examined in the laboratory under a microscope. To determine whether a patient has mesothelioma, this will have to be done. How the biopsy is carried out depends on which part of the body is targeted:


Targeting either the chest or abdominal area
Fine-needle aspiration - a small needle is inserted into the abdomen and chest and some fluid or piece of tissue is removedTargeting the chest area
Thoracoscopy - the surgeon inserts a thoracoscope through a small incision between the patient's ribs. A thoracoscope is an endoscope for examination of the chest cavity - it is a tube with a small camera at the end. The surgeon removes a piece of tissue with special tools.Thoracotomy - in this surgical intervention, the chest is opened between the ribs so that the surgeon can see the target area and check for signs of cancer. Some tissue may also be removed and sent to the laboratory for testing.Targeting the abdominal area
Laparoscopy - a small incision is made in the abdominal wall, a laparoscope is inserted through the incision into the abdomen, where the surgeon can have a look. The laparoscope is a long tube with a camera at the end. With specialized tools, tissue samples can be removed.Laparotomy - the surgeon opens the abdomen and has a look. Sometimes tissue samples may be removed and sent to the lab.When the tissue or fluid sample is viewed through a microscope, the pathologist can tell whether there is malignancy (e.g. malignant mesothelioma), what types of cells are involved, and how advanced the cancer is. How advanced a cancer is, defining it, is called Staging.

Staging - in medicine, specifically cancer, staging is the process of carrying out tests and examinations to determine the extent of the cancer, how advanced it is, and whether it has metastasized (spread from its original site to other parts of the body).


As soon as mesothelioma has been confirmed (diagnosed), other tests will be ordered to help determine the stage of the cancer. These may include such scans as CT, MRI (magnetic resonance imaging), PET (positron emission tomography), or a chest X-ray. What type of scan is used depends on several different factors.


When all the data is gathered together, the health care professional will assign the cancer a stage. The staging below is for pleural mesothelioma (lungs): Stage 1 - the cancer is localized. It is still inside the lining around the lung. It has not spread out.Stage 2 - the cancer may have spread to a lung or the diaphragm.Stage 3 - the cancer may have reached the lymph nodes, and possibly other parts of the chestStage 4 - the cancer has either spread more extensively in the chest, or may even have reached other parts of the body far from the original site. It may have reached other lymph nodes, or even the brain.The treatment the doctor will recommend depends on several factors, including: Where the cancer isThe stage of the cancer (how advanced it is)The patient's general health and ageSadly, this type of cancer is usually spotted when it has been progressing for a while. Add to this the fact that mesothelioma is usually an aggressive type of cancer, and you have two reasons why so few patients are cured.

If the cancer is very advanced, the tumor(s) can no longer be surgically removed. The only option left, in many cases, is to control the cancer, try to slow down its progress, and focus on making the patient as comfortable as possible.


It is vital that the medical team explains all the options to the patient - including their pros and cons - and if necessary, to his/her loved ones and/or caregivers. Fighting the cancer aggressively may mean enduring very unpleasant side effects, while just focusing on pain and quality of life for the remaining time, might be a better option. This is something the patient needs to discuss thoroughly with the medical team, and perhaps family members or close friends.


Surgery - this means removing tumors by surgery. Surgery is usually only an option during the early stages of the cancer. It may remove the whole cancer, or at least reduce some symptoms and slow it down. Fluid accumulation in the lung area - surgery may be recommended if there is fluid accumulation in the chest, resulting in breathing difficulties. The fluid is drained with a tube or catheter. A drug may be injected into the chest to stop a recurrence of fluid build-up. Drugs, such as tetracycline, talc powder, or bleomycin are instilled inside the space between the two layers of tissue lining the lungs (pleura); this causes inflammation, making the two pleura tack together, leaving no space for fluid build-up. Treatment for preventing this type of fluid build-up is called pleurodesis.Pleurectomy or peritonectomy - the lining around the lungs or abdominal cavity may be surgically removed. The aim is to relieve mesothelioma symptoms.Debulking - removing as much of the tumor as possible, if it is not possible to remove all of it.Removing a lung - signs and symptoms may be relieved if the surgeon removes the affected lung and its surrounding tissue. This will be followed by radiotherapy.Chemotherapy - if tumors cannot be surgically removed, chemotherapy may help shrink them, as well as to slow down their progress. Neoadjuvant chemotherapy may also be recommended - administering chemotherapy before surgery which can make it easier to remove a tumor. Chemotherapy used after surgery to try to prevent recurrence is called adjuvant chemotherapy.

Radiotherapy - also known as radiation therapy. For those with pleural mesothelioma, it may help relieve symptoms. Radiotherapy is sometimes administered to prevent metastasis after biopsy or surgery.


Clinical trials - human studies using novel treatment methods. The patient should discuss what the trial is about, as well as what to expect realistically, thoroughly with the doctor.

Cancer is a very unpredictable disease, and providing an accurate prognosis is not easy.

In general, prognoses for patients with mesothelioma are not encouraging. Malignant mesothelioma is a very aggressive type of cancer; it also has a long latency period. In the majority of cases, the disease is only detected when it is already in an advanced stage.


In most cases, survival for pleural malignant mesothelioma after diagnosis is no more than one or two years. The patient needs to bear in mind that there are exceptions, and new treatments are being researched and appear all the time.


Visit our asbestos / mesothelioma section for the latest news on this subject. Sources: The National Health Service (UK), CDC (Centers for Disease Control and Prevention, USA), WHO (World Health Organization), NIH (National Institutes of Health, USA), HSA (Health and Safety Executive, UK). Please use one of the following formats to cite this article in your essay, paper or report:


MLA

Christian Nordqvist. "What Is Mesothelioma? Cancer From Asbestos." Medical News Today. MediLexicon, Intl., 16 Nov. 2011. Web.
16 Jan. 2012. APA

Please note: If no author information is provided, the source is cited instead.



Note: Any medical information published on this website is not intended as a substitute for informed medical advice and you should not take any action before consulting with a health care professional. For more information, please read our terms and conditions.



View the original article here